1587 related articles for article (PubMed ID: 18600190)
1. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
Goh P; Lim FS; Han HH; Willems P
Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
[TBL] [Abstract][Full Text] [Related]
5. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
Knuf M; Zepp F; Helm K; Maurer H; Prieler A; Kieninger-Baum D; Douha M; Willems P
Eur J Pediatr; 2012 Mar; 171(3):463-70. PubMed ID: 21935584
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
Knuf M; Habermehl P; Zepp F; Mannhardt W; Kuttnig M; Muttonen P; Prieler A; Maurer H; Bisanz H; Tornieporth N; Descamps D; Willems P
Pediatr Infect Dis J; 2006 Jan; 25(1):12-8. PubMed ID: 16395096
[TBL] [Abstract][Full Text] [Related]
7. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
Leung JH; Hirai HW; Tsoi KK
Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133
[TBL] [Abstract][Full Text] [Related]
9. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
[TBL] [Abstract][Full Text] [Related]
10. The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy.
Durando P; Esposito S; Bona G; Cuccia M; Desole MG; Ferrera G; Gabutti G; Pellegrino A; Salvini F; Henry O; Povey M; Marchetti F
Vaccine; 2016 Aug; 34(36):4278-84. PubMed ID: 27423382
[TBL] [Abstract][Full Text] [Related]
11. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
Nolan T; McIntyre P; Roberton D; Descamps D
Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.
Lalwani S; Chatterjee S; Balasubramanian S; Bavdekar A; Mehta S; Datta S; Povey M; Henry O
BMJ Open; 2015 Sep; 5(9):e007202. PubMed ID: 26362659
[TBL] [Abstract][Full Text] [Related]
14. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.
Shinefield HR; Black S; Kuter BJ
J Infect Dis; 2008 Mar; 197 Suppl 2():S152-5. PubMed ID: 18419390
[TBL] [Abstract][Full Text] [Related]
15. The combination measles, mumps, rubella and varicella vaccine in healthy children.
Arbeter AM; Baker L; Starr SE; Plotkin SA
Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864
[TBL] [Abstract][Full Text] [Related]
16. Combination measles, mumps, rubella and varicella vaccine.
Arbeter AM; Baker L; Starr SE; Levine BL; Books E; Plotkin SA
Pediatrics; 1986 Oct; 78(4 Pt 2):742-7. PubMed ID: 3763291
[TBL] [Abstract][Full Text] [Related]
17. A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile.
Czajka H; Schuster V; Zepp F; Esposito S; Douha M; Willems P
Vaccine; 2009 Nov; 27(47):6504-11. PubMed ID: 19665608
[TBL] [Abstract][Full Text] [Related]
18. A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process.
Marshall GS; Senders SD; Shepard J; Twiggs JD; Gardner J; Hille D; Hartzel J; Valenzuela R; Stek JE; Helmond FA
Hum Vaccin Immunother; 2016 Aug; 12(8):2188-2196. PubMed ID: 27149048
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months.
Vesikari T; Karvonen A; Lindblad N; Korhonen T; Lommel P; Willems P; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2010 Jun; 29(6):e47-56. PubMed ID: 20508478
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad(®)) in infants from 9 months of age.
Vesikari T; Becker T; Gajdos V; Fiquet A; Thomas S; Richard P; Baudin M
Vaccine; 2012 Apr; 30(20):3082-9. PubMed ID: 22406278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
